Neurocognitive function in long-term treated schizophrenia: A five-year follow-up study

Psychiatry Research

Volumn 200, Issue 2-3, 2012, Pages 144-152

  Ekerholm, Maria ^a   Firus Waltersson, Svala ^a   Fagerberg, Thomas ^a   Söderman, Erik ^a   Terenius, Lars ^a   Agartz, Ingrid ^a,b,c   Jönsson, Erik Gunnar ^a   Nyman, Håkan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF OSLO   (Norway)

^c DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

Longitudinal follow up studies; Neurocognition; Neuropsychological tests; Schizophrenia

Indexed keywords

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE DURATION; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MALE; MENTAL TASK; NEUROPSYCHOLOGICAL TEST; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; TASK PERFORMANCE;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; COGNITION; EXECUTIVE FUNCTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VERBAL LEARNING;

EID: 84872385889     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.05.008     Document Type: Article

References (76)

1. Agartz I., Sedvall G.C., Terenius L., Kulle B., Frigessi A., Hall H., Jönsson E.G. BDNF gene variants and brain morphology in schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2006, 141B:513-523.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text revision (DSM-IV-TR) 2000, American Psychiatric Association, Washington, DC.
3. Andreasen N.C. Schizophrenia: the fundamental questions. Brain Research. Brain Research Reviews 2000, 31:106-112.
4. Andreou D., Saetre P., Lundmark P., Hansen T., Timm S., Melle I., Djurovic S., Andreassen O.A., Werge T., Hall H., Agartz I., Terenius L., Jönsson E.G. Tyrosine hydroxylase (TH) Val81Met polymorphism: lack of association with schizophrenia. Psychiatric Genetics 2009, 19:273-274.
5. Arnborg S., Agartz I., Hall H., Jönsson E., Sillén A., Sedvall G. Data mining in schizophrenia research-preliminary analysis 2002, 27-38. Springer Verlag, Berlin. T. Elomaa, H. Mannila, H. Toivonen (Eds.).
6. Baddeley A. Working memory. Science 1992, 255:556-569.
7. Birkett P., Sigmundsson T., Sharma T., Toulopoulou T., Griffiths T.D., Reveley A., Murray R. Reaction time and sustained attention in schizophrenia and its genetic predisposition. Schizophrenia Research 2007, 95:76-85.
8. Bowie C.R., Reichenberg A., McClure M.M., Leung W.L., Harvey P.D. Age-associated differences in cognitive performance in older community dwelling schizophrenia patients: differential sensitivity of clinical neuropsychological and experimental information processing tests. Schizophrenia Research 2008, 106:50-58.
9. Bozikas V.P., Kosmidis M.H., Kiosseoglou G., Karavatos A. Neuropsychological profile of cognitively impaired patients with schizophrenia. Comprehensive Psychiatry 2006, 47:136-143.
10. Brown S. Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry 1997, 171:502-508.
11. Caprini S., Saetre P., Melle I., Djurovic S., Andreassen O.A., Skjødt C., Duong L., Werge T., Hall H., Agartz I., Terenius L., Jönsson E.G. Lack of association between two dopamine D2 receptor gene (DRD2) polymorphisms and schizophrenia. Psychiatric Genetics 2011, 21:214-215.
12. Carlborg A., Winnerbäck K., Jönsson E.G., Jokinen J., Nordström P. Suicide in schizophrenia. Expert Review of Neurothereapeutics 2010, 10:1153-1164.
13. Censits D.M., Ragland J.D., Gur R.C., Gur R.E. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophrenia Research 1997, 24:289-298.
14. Chen W.J., Hsiao C.K., Hsiao L.L., Hwu H.G. Performance of the continuous performance test among community samples. Schizophrenia Bulletin 1998, 24:163-174.
15. Davidson M., Harvey P., Welsh K.A., Powchik P., Putnam K.M., Mohs R.C. Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. American Journal of Psychiatry 1996, 153:1274-1279.
16. DeLisi L.E., Hoff A.L. Failure to find progressive temporal lobe volume decreases 10 years subsequent to a first episode of schizophrenia. Psychiatry Research 2005, 138:265-268.
17. Ekholm B., Ekholm A., Adolfsson R., Vares M., Ösby U., Sedvall G.C., Jönsson E.G. Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nordic Journal of Psychiatry 2005, 59:457-464.
18. Friedman J.I., Harvey P.D., Coleman T., Moriarty P.J., Bowie C., Parrella M., White L., Adler D., Davis K.L. Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. American Journal of Psychiatry 2001, 158:1441-1448.
19. Fucetola R., Seidman L.J., Kremen W.S., Faraone S.V., Goldstein J.M., Tsuang M.T. Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biological Psychiatry 2000, 48:137-146.
20. Gold S., Arndt S., Mosnik D., Nopoulos P., O'Leary D.S., Andreasen N.C. The relationship of symptom dimensions and neuropsychological function in first episode and recent onset schizophrenia: a five year longitudinal study. Schizophrenia Research 1997, 24:103-104.
21. Gold S., Arndt S., Nopoulos P., O'Leary D.S., Andreasen N.C. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. American Journal of Psychiatry 1999, 156:1342-1348.
22. Hartberg C.B., Lawyer G., Nyman H., Jönsson E.G., Haukvik U.K., Saetre P., Bjerkan P.S., Andreassen O.A., Hall H., Agartz I. Investigating relationships between cortical thickness and cognitive performance in patients with schizophrenia and healthy adults. Psychiatry Research 2010, 182:123-133.
23. Harvey P.D., Sharma T. Understanding and Treating Cognition in Schizophrenia. A Clinicians Handbook 2002, Cromwell Press, Trowbridge.
24. Harvey P.D., Silverman J.M., Mohs R.C., Parrella M., White L., Powchik P., Davidson M., Davis K.L. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biological Psychiatry 1999, 45:32-40.
25. Haukvik U.K., Lawyer G., Bjerkan P.S., Bhandari Hartberg C., Jönsson E.G., McNeil T., Agartz I. Cerebral cortical thickness and a history of obstetric complications in schizophrenia. Journal of Psychiatric Research 2009, 43:1287-1293.
26. Haukvik U.K., McNeil T., Nesvåg R., Söderman E., Jönsson E., Agartz I. No effect of obstetric complications on basal ganglia volumes in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:619-623.
27. Haukvik U.K., Saetre P., McNeil T., Bjerkan P.S., Andreassen O.A., Werge T., Jönsson E.G., Agartz I. An exploratory model for G×E interaction on hippocampal volume in schizophrenia; obstetric complications and hypoxia-related genes. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:1259-1265.
28. Haukvik, U.K., Schaer, M., Nesvåg, R., McNeil, T., Hartberg, C.B., Jönsson, E.G., Eliez, S., Agartz, I., 2012. Cortical folding in Broca's area relates to obstetric complications in schizophrenia patients and healthy controls. Psychological Medicine 42, 1329-1337.
29. Heaton R.K., Chelune G.J., Talley J.L., Kay G.G., Curtiss G. Wisconsin card sorting test manual, revised and expanded 1993, Psychological Assessment Resources, Odessa, FL.
30. Hoff A.L., Wieneke M., Faustman W.O., Horon R., Sakuma M., Blankfeld H., Espinoza S., DeLisi L.E. Sex differences in neuropsychological functioning of first-episode and chronically ill schizophrenic patients. American Journal of Psychiatry 1998, 155:1437-1439.
31. Hoff A.L., Sakuma M., Wieneke M., Horon R., Kushner M., DeLisi L.E. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. American Journal of Psychiatry 1999, 156:1336-1341.
32. Hoff A.L., Svetina C., Shields G., Stewart J., DeLisi L.E. Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. Schizophrenia Research 2005, 78:27-34.
33. Holtze M., Saetre P., Engberg G., Schwieler L., Werge T., Andreassen O.A., Hall H., Terenius L., Agartz I., Jönsson E.G., Schalling M., Erhardt S. Kynurenine 3-monooxygenase polymorphisms-relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. Journal of Psychiatry and Neuroscience 2012, 37:53-57.
34. Holtze M., Saetre P., Erhardt S., Schwieler L., Werge T., Hansen T., Nielsen J., Djurovic S., Melle I., Andreassen O.A., Hall H., Terenius L., Agartz I., Engberg G., Jönsson E.G., Schalling M. Kynurenine 3-monooxygenase (KMO) polymorphisms in schizophrenia: an association study. Schizophrenia Research 2011, 127:270-272.
35. Jönsson E.G., Abou Jamra R., Schumacher J., Flyckt L., Edman G., Forslund K., Mattila-Evenden M., Rylander G., Åsberg M., Bjerkenstedt L., Wiesel F.-A., Propping P., Cichon S., Nöthen M.M., Sedvall G.C. No association between a putative functional promoter variant in the dopamine Β-hydroxylase gene and schizophrenia. Psychiatric Genetics 2003, 13:175-178.
36. Jönsson E.G., Cichon S., Gustavsson J.P., Grünhage F., Forslund K., Mattila-Evenden M., Rylander G., Åsberg M., Farde L., Propping P., Nöthen M.M. Association between a promoter dopamine D2 receptor gene variant and the personality trait detachment. Biological Psychiatry 2003, 53:577-584.
37. Jönsson E.G., Cichon S., Schumacher J., Abou Jamra R., Schulze T.G., Deschner M., Forslund K., Hall H., Propping P., Czerski P.M., Dmitrak-Weglarz M., Kapelski P., Driessen M., Maier W., Hauser J., Rietschel M., Nöthen M.M. Association study of a functional promoter polymorphism in the XBP1 gene and schizophrenia. American Journal of Medical Genetics 2006, 141B:71-75.
38. Jönsson E.G., Edman-Ahlbom B., Sillén A., Gunnar A., Kulle B., Frigessi A., Vares M., Ekholm B., Wode-Helgodt B., Schumacher J., Cichon S., Agartz I., Sedvall G.C., Hall H., Terenius L. Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006, 30:924-933.
39. Jönsson E.G., Flyckt L., Burgert E., Crocq M.-A., Forslund K., Mattila-Evenden M., Rylander G., Åsberg M., Nimgaonkar V.L., Edman G., Bjerkenstedt L., Wiesel F.-A., Sedvall G.C. Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatric Genetics 2003, 13:1-12.
40. Jönsson E.G., Larsson K., Vares M., Hansen T., Wang A.G., Djurovic S., Rønningen K.S., Andreassen O.A., Agartz I., Werge T., Terenius L., Hall H. Two methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms, schizophrenia and bipolar disorder: an association study. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2008, 147B:976-982.
41. Jönsson, E.G., Saetre, P., Nyholm, H., Djurovic, S., Melle, I., Andreassen, O.A., Skjødt, C., Thygesen, J.H., Werge, T., Hall, H., Agartz, I., Terenius, L. Lack of association between the regulator of G-protein signalling 4 (RGS4) rs951436 polymorphism and schizophrenia. Psychiatric Genetics, in press. http://dx.doi.org/10.1097/YPG.0b013e32834f3558.
42. Jönsson E.G., Saetre P., Vares M., Andreou D., Larsson K., Timm S., Rasmussen H.B., Djurovic S., Melle I., Andreassen O.A., Agartz I., Werge T., Hall H., Terenius L. DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association study. Neuropsychobiology 2009, 59:142-150.
43. Jönsson E.G., Saetre P., Vares M., Strålin P., Levander S., Lindström E. Use of antipsychotics-an analysis of lifetime treatment in 66 patients with psychoses. Psychiatry Research 2011, 187:80-88.
44. Jönsson E.G., Sillén A., Vares M., Ekholm B., Terenius L., Sedvall G.C. Dopamine D2 receptor gene Ser311Cys variant and schizophrenia: association study and meta-analysis. American Journal of Medical Genetics 2003, 119B:28-34.
45. Karilampi U., Helldin L., Hjarthag F., Norlander T., Archer T. Verbal learning in schizopsychotic outpatients and healthy volunteers as a function of cognitive performance levels. Archives of Clinical Neuropsychology 2007, 22:161-174.
46. Kelly B.D., Lane A., Lawyer G., Agartz I., McNeil T.F., Henriksson K.M., Nesvåg R. Craniofacial dysmorphology and cortical thickness in men with schizophrenia. Schizophrenia Research 2008, 103:322-323.
47. Lawyer G., Nesvåg R., Varnäs K., Frigessi A., Agartz I. Investigating possible subtypes of schizophrenia patients and controls based on brain cortical thickness. Psychiatry Research 2008, 164:254-264.
48. Lawyer G., Nesvåg R., Varnäs K., Okugawa G., Agartz I. Grey and white matter proportional relationships in the cerebellar vermis altered in schizophrenia. Cerebellum 2009, 8:52-60.
49. Lawyer G., Nyman H., Agartz I., Arnborg S., Jönsson E.G., Sedvall G.C., Hall H. Morphological correlates to cognitive dysfunction in schizophrenia as studied with Bayesian regression. BMC Psychiatry 2006, 6:31.
50. Lezak M.D. Neuropsychological assessment 1995, Oxford University Press, New York.
51. Lindholm Carlström, E., Saetre, P., Rosengren, A., Thygesen, J.H., Djurovic, S., Melle, I., Andreassen, O.A., Werge, T., Agartz, I., Hall, H., Terenius, L., Jönsson, E.G., 2012. Association between a genetic variant in the serotonin transporter gene (SLC6A4) and suicidal behavior in patients with schizophrenia. Behavioral and Brain Functions 8, 24.
52. Liu S.K., Hsieh M.H., Hwang T.J., Hwu H.G., Liao S.C., Lin S.H., Chen W.J. Re-examining sustained attention deficits as vulnerability indicators for schizophrenia: stability in the long term course. Journal of Psychiatric Research 2006, 40:613-621.
53. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiological Reviews 2008, 30:67-76.
54. Messinis L., Tsakona I., Malefaki S., Papathanasopoulos P. Normative data and discriminant validity of Rey's verbal learning test for the Greek adult population. Archives of Clinical Neuropsychology 2007, 22:739-752.
55. Mitrushina M., Boone K.B., Razani J., D'Elia L.F. Handbook of normative data for neuropsychological assessment 2005, Oxford University Press, New York.
56. Morrens M., Hulstijn W., Sabbe B. Psychomotor slowing in schizophrenia. Schizophrenia Bulletin 2007, 33:1038-1053.
57. Nesvåg R., Frigessi A., Jönsson E.G., Agartz I. Effects of alcohol consumption and antipsychotic medication on brain morphology in schizophrenia. Schizophrenia Research 2007, 90:52-61.
58. Nesvåg R., Lawyer G., Varnas K., Fjell A.M., Walhovd K.B., Frigessi A., Jönsson E.G., Agartz I. Regional thinning of the cerebral cortex in schizophrenia: effects of diagnosis, age and antipsychotic medication. Schizophrenia Research 2008, 98:16-28.
59. Nesvåg R., Saetre P., Lawyer G., Jönsson E.G., Agartz I. The relationship between symptom severity and regional cortical and grey matter volumes in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009, 33:482-490.
60. Nikulin V.V., Jönsson E.G., Brismar T. Attenuation of long range temporal correlations in the amplitude dynamics of alpha and beta neuronal oscillations in patients with schizophrenia. Neuroimage 2012, 61:162-169.
61. Palmer B.A., Pankratz V.S., Bostwick J.M. The lifetime risk of suicide in schizophrenia: a reexamination. Archives of General Psychiatry 2005, 62:247-253.
62. Perry W., Heaton R.K., Potterat E., Roebuck T., Minassian A., Braff D.L. Working memory in schizophrenia: transient "online" storage versus executive functioning. Schizophrenia Bulletin 2001, 27:157-176.
63. Reite M., Cullum C.M., Stocker J., Teale P., Kozora E. Neuropsychological test performance and MEG-based brain lateralization: sex differences. Brain Research Bulletin 1993, 32:325-328.
64. Rund B.R. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophrenia Bulletin 1998, 24:425-435.
65. Saetre P., Agartz I., De Franciscis A., Lundmark P., Djurovic S., Kähler A., Andreassen O.A., Jakobsen K.D., Rasmussen H.B., Werge T., Hall H., Terenius L., Jönsson E.G. Association between a disrupted-in-schizophrenia 1 (DISC1) single nucleotide polymorphism and schizophrenia in a combined Scandinavian case control sample. Schizophrenia Research 2008, 106:237-241.
66. Saetre P., Lundmark P., Wang A., Hansen T., Rasmussen H.B., Djurovic S., Melle I., Andreassen O.A., Werge T., Agartz I., Hall H., Terenius L., Jönsson E.G. The tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility and suicidal behavior: a multi-centre case-control study and meta-analysis. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2010, 153B:387-396.
67. Saetre P., Vares M., Werge T., Andreassen O.A., Arinami T., Ishiguro H., Nanko S., Tan E.C., Han D.H., Roffman J.L., Muntjewerff J.-W., Jagodzinski P.P., Kempisty B., Hauser J., Vilella E., Betcheva E., Nakamura Y., Regland B., Agartz I., Hall H., Terenius L., Jönsson E.G. Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and age of onset in schizophrenia: a combined analysis of independent samples. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2011, 156:215-224.
68. Saykin A.J., Gur R.C., Gur R.E., Mozley P.D., Mozley L.H., Resnick S.M., Kester D.B., Stafiniak P. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Archives of General Psychiatry 1991, 48:618-624.
69. Vares M., Ekholm A., Sedvall G.C., Hall H., Jönsson E.G. Characterisation of patients with schizophrenia and related psychosis: evaluation of different diagnostic procedures. Psychopathology 2006, 39:286-295.
70. Vares M., Saetre P., Deng H., Cai G., Liu X., Hansen T., Rasmussen H.B., Werge T., Melle I., Djurovic S., Andreassen O.A., Agartz I., Hall H., Terenius L., Jönsson E.G. Association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and age of onset in schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2010, 153B:610-618.
71. Vares M., Saetre P., Strålin P., Levander S., Lindström E., Jönsson E.G. Concomitant medication of psychoses in a life-time perspective. Human Psychopharmacology: Clinical and Experimental 2011, 26:322-331.
72. Varnäs K., Lawyer G., Jönsson E.G., Kulle B., Nesvåg R., Hall H., Terenius L., Agartz I. Brain-derived neurotrophic factor polymorphisms and frontal cortex morphology in schizophrenia. Psychiatric Genetics 2008, 18:177-183.
73. Vega U., Silberman C., Laks J., Braga R.J., Burdick K.E. Association of education and cognitive status in Brazilian elderly institutionalized patients with schizophrenia. Schizophrenia Research 2005, 78:107-109.
74. Wechsler D. The Wechsler adult intelligence scale-III 1997, Psychological corporation, New York.
75. Williamsson P. Mind, brain and schizophrenia 2005, Oxford University Press, Oxford; New York.
76. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 2003, 64:663-667.